Corcept Therapeutics Q3 Earnings Call Highlights
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Corcept Therapeutics (NASDAQ:CORT) reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the launch of ovarian cancer treatment Lifyorli lifted results. Net income totaled
Directly affected
- CORT Corcept Therapeutics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Corcept Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and is a peer of Corcept Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson is a peer of Corcept Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+8.9% 30d
AbbVie is a peer of Corcept Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+4.6% 17d
Merck is a peer of Corcept Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+7.7% 30d
Abbott Laboratories is a peer of Corcept Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CORT | +5.36% | -1.04% | base | after close | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| LLY | -8.42% | +0.54% | base | after close | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | after close | after close | after close | after close |
| ABBV | +0.13% | +3.12% | base | after close | after close | after close | after close |
| MRK | -2.47% | +3.37% | base | after close | after close | after close | after close |
| ABT | -6.15% | -2.89% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Corcept Therapeutics Q3 Earnings Call Highlights Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | +3.12% | final price |
| ABBV | five days earlier | +0.13% | final price |
| ABT | three days earlier | -2.89% | final price |
| ABT | five days earlier | -6.15% | final price |
| CORT | three days earlier | -1.04% | final price |
| CORT | five days earlier | +5.36% | final price |
| JNJ | three days earlier | +2.66% | final price |
| JNJ | five days earlier | +1.93% | final price |
| LLY | three days earlier | +0.54% | final price |
| LLY | five days earlier | -8.42% | final price |
| MRK | three days earlier | +3.37% | final price |
| MRK | five days earlier | -2.47% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 51 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 33 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 47 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Corcept Therapeutics Q3 Earnings Call Highlights” looks
12 out of 100
“Corcept Therapeutics Q3 Earnings Call Highlights” scores 12 out of 100. The score uses 1 sources.